InSite Vision Commences Phase 1/2 Clinical Study of ISV-303 for Post-Surgical Ocular Pain and Swelling Following Cataract and Other Surgeries

August 24, 2010

InSite Vision Incorporated, a company developing ophthalmic therapeutics, today announced the initiation of a Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. ISV-303 combines a low dose of the non-steroidal anti-inflammatory (NSAID) bromfenac with InSite Vision’s proprietary DuraSite(R) technology. The randomized, placebo-controlled Phase 1/2 clinical trial is designed to evaluate the safety, efficacy and pharmacokinetics of ISV-303.

InSite’s DuraSite sustained delivery technology is a patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and can be customized for delivering a wide variety of potential drug candidates. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite(R) (azithromycin ophthalmic solution) 1% and Besivance(TM) (besifloxacin ophthalmic suspension) 0.6%.

ISV-303 is intended to extend the duration of drug residence on the eye’s surface to facilitate better penetration and thus reduce dosing, while potentially improving the efficacy profile. ISV-303 combines a low concentration of bromfenac (Xibrom(TM), marketed by ISTA Pharmaceuticals) with DuraSite, InSite Vision’s proven bioadhesive polymer technology. In preclinical studies, ISV-303 demonstrated a superior delivery and ocular distribution profile when compared to the commercially available bromfenac eye drop.

Read the full press release on InSite Vision’s website.

 

 



Comments

Jump down to form below to submit your own comments

Trackback URL
http://eyedocnews.com/003367-insite-vision-commences-phase-12-clinical-study-of-isv-303-for-post-surgical-ocular-pain-and-swelling/trackback/

Have insights to contribute? Please submit your comment below